Measuring patient-centred long-term outcome following a bloodstream infection: a pilot study.


Journal

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases
ISSN: 1469-0691
Titre abrégé: Clin Microbiol Infect
Pays: England
ID NLM: 9516420

Informations de publication

Date de publication:
Feb 2020
Historique:
received: 23 08 2019
revised: 06 10 2019
accepted: 08 10 2019
pubmed: 28 10 2019
medline: 26 9 2020
entrez: 27 10 2019
Statut: ppublish

Résumé

To evaluate the sequential organ failure assessment (SOFA) and modified SOFA (mSOFA) scoring and a novel performance score based on the Karnofsky score for measuring outcome following a bloodstream infection (BSI). This prospective observational cohort study assessed patients with BSI for mortality and functional outcomes with a novel performance score: the functional bloodstream infection score (FBIS). We also tested the SOFA and, given the difficulties with measuring SOFA on ward-based patients, the mSOFA over the first 7 days following a BSI for their association with outcomes. One hundred participants were prospectively recruited. Mortality at 52 weeks following BSI was 21% (21/100). Only 57% of survivors (39/69) were at their baseline functional status at 52 weeks. Stable or improved SOFA/mSOFA over the first 7 days was associated with survival and return to premorbid performance score (risk ratio 3.2, 95%CI 1.3-9.4, p < 0.01). The acute change in SOFA/mSOFA was associated with 52-week survival and return to premorbid functional performance. The FBIS measurement represents a simple and easy-to-apply measure of functional performance for patients with BSI and was associated with a high response rate (89%) from participants.

Identifiants

pubmed: 31654791
pii: S1198-743X(19)30544-0
doi: 10.1016/j.cmi.2019.10.011
pii:
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

257.e1-257.e4

Informations de copyright

Copyright © 2019 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Auteurs

J F McNamara (JF)

The University of Queensland, Centre for Clinical Research, Herston, Brisbane, Australia; The Prince Charles Hospital, Brisbane, Australia. Electronic address: mcnamarajfg@gmail.com.

P N A Harris (PNA)

The University of Queensland, Centre for Clinical Research, Herston, Brisbane, Australia; Pathology Queensland, Central Laboratory, Royal Brisbane and Women's Hospital, Herston, Australia.

M D Chatfield (MD)

The University of Queensland, Centre for Clinical Research, Herston, Brisbane, Australia.

P Lorenc (P)

The University of Queensland, Centre for Clinical Research, Herston, Brisbane, Australia.

D L Paterson (DL)

The University of Queensland, Centre for Clinical Research, Herston, Brisbane, Australia; The Royal Brisbane and Women's Hospital, Brisbane, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH